Histological Changes of Skin Induced with Psoriasis and Treated with Aloe Vera Gel in Rats

Abstract

Psoriasis is a common chronic immune-mediated inflammatory skin disease with features of epidermal hyperproliferation and infiltration of leukocytes. The current work was performed to assess the histopathological changes of imiquimod (IMQ) induced psoriatic skin lesions and investigate the beneficial therapeutic targets after topical application of Aloe vera (AV) gel in experimental rats. A total of 24 male Wistar albino rats were divided into four groups: G1 (healthy control), G2 (psoriasis-induced control), G3 (psoriasis + AV gel treatment), and G4 (psoriasis + Tazarotene treatment). Histological analysis revealed that AV gel significantly reduced keratosis, acanthosis, and perivascular inflammation, comparable to the standard Tazarotene treatment. The stratum corneum thickness was significantly decreased in treated groups. These findings suggest that AV gel holds promise as a natural therapeutic option for psoriasis management.

Keywords:

Psoriasis, Aloe vera, Imiquimod, Tazarotene, Keratinocyte Histopathology

References

Egeberg A, Andersen YM, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort. BMJ Open. 2019;9(3):e028116.

Sewerin P, Brinks R, Schneider M, Haase I, Vordenbنumen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2019;78(2):286–287.

Parisi R, Iskandar IY, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.

Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81.

Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA Dermatol. 2021;157(8):956–965.

Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347.

Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Am J Clin Dermatol. 2019;20(4):537–552.

Lowes MA, Suلrez-Fariٌas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.

Johnston A, Guzman AM, Swindell WR, et al. Early tissue responses in psoriasis to IL-17 inhibition overcome resistance to anti-TNF therapy. Front Med. 2022;9:827040.

Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis with topical therapies. J Am Acad Dermatol. 2019;80(4):1029–1072.

Kumar R, Singh AK, Gupta A, et al. Therapeutic potential of Aloe vera—A miracle gift of nature. Phytomedicine. 2019;60:152996.

Mariana C, Musuc AM, Popa M, Calderon Moreno J. Aloe vera-Based Hydrogels for Wound Healing: Properties and Therapeutic Effects. Gels. 2023;9(7):539.

Kim ST, Pressman P, Clemens R, et al. The absence of genotoxicity of Aloe vera beverages: A review of the literature. Food Chem Toxicol. 2023;174:113628.

Reynolds T, Dweck AC. Aloe vera leaf gel: a review update. J Ethnopharmacol. 2020;265:113–529.

Silvana TLJ, Barbosa RM, Albuquerque AC, et al. Development and Characterization of Aloe vera Mucilaginous-Based Hydrogels for Psoriasis Treatment. J Compos Sci. 2022;6(8):231.

Lee JY, Chung E, Lee KJ, et al. Effects of Aloe vera gel on wound healing and inflammation in rat skin. Molecules. 2021;26(6):1617.

Deep A, Kumar D, Bansal N, et al. Understanding mechanistic aspects and therapeutic potential of natural substances as anticancer agents. Phytomed Plus. 2023;3:100418.

Ray A, Aswatha SM. Influence of growth periods on Aloe vera gel composition and bioactivity. Ind Crops Prod. 2013;48:36–42.

Jales ST, Barbosa RM, Duarte LHV, et al. Aloe vera hydrogels for skin therapy. J Compos Sci. 2022;6(8):231.

Chelu M, Musuc AM, Popa M, et al. Aloe vera hydrogels in dermatological applications. Gels. 2023;9(7):539.

Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.

Pandey A, Shukla AK, Dubey RC. Important phytochemicals and their role in psoriasis. J Appl Nat Sci. 2021;13(3):880–896.

Lariosa-Willingham K, Leonoudakis D, Simon F, et al. Imiquimod-induced pruritus in rats: a model for antipruritic treatments. BMC Res Notes. 2023;16:348.

Ortiz-Lopez LI, Choudhary V, Bollag WB. Keratinocytes are more than innocent bystanders in psoriasis. Psoriasis: Targets Ther. 2022;12:73–87.

Mils V, Basset-Séguin N, Molès J, et al. Comparative analysis of normal and psoriatic skin in vivo and in vitro. Histochem Cell Biol. 1994;58(1):77–86.

Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient’s life cumulative? Dermatol Ther. 2020;10(1):53–66.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.

Boehncke WH, Schِn MP. Psoriasis. Lancet. 2015;386(9997):983–994.

Fredriksson T,Pettersson U. Severe psoriasis –Oral therapy with a new retinoid. Dermatologica. 2009;157:238-244. doi: 10.1159/000250839.

Baek JO, Byamba D, Wu WH, Kim TG and Lee MG. Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress. Arch Dermatol Res. 2012;304:699-706. doi:10.1007/s00403-012-1272-y.

Barygina VV, Becatti M, Soldi G, Prignano F, Lotti T, Nassi P, et al. Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy. Redox Rep. 2013;18(3):100-106. doi: 10.1179/1351000213Y.0000000045